euroinflammation in the pathogenesis and progression of Parkinson's disease - Neuroinflammation in Parkinson's disease

Academisch Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•Inclusion criteria (healthy volunteers)
•Age over 40
•Informed consent;Inclusion criteria (patients)
•-Age over 40
•-Informed consent.
•-Regarded by the treating physician to have competence of judgement.
•-Compliance with the criteria for possible or probable PD as proposed by Gelb, Oliver and Gilman [1999]
•-de novo PD without PD medication, or advanced PD with Hoehn and Yahr stage of at least 2.

•Exclusion criteria (all PET-study subjects)
•- Prior cardiovascular brain disease, other brain disease (including former traumatic contusion)
•- Evidence of any general medical disease, e.g. significant kidney or liver disease, evidence of autoimmune disease.
•- Use of anti-inflammatory medication: NSAID*s and steroids.
•- Use of benzodiazepines. Benzodiazepines have affinity for the PBR receptor that binds the PET tracer PK11195 and can interfere with the study.
•- Abnormalities at clinical neurological examination
•- Pregnancy in women of childbearing potential.
•- Exposure to a significant amount of radiation in the past year.
•- Radiological workers.

发起方